ADAM17-siRNA对MCF-7人乳腺癌细胞增殖的影响
|
摘要
目的:
乳腺癌是女性最常见的恶性肿瘤之一,近年来其发病率逐年上升。其具体发生机制至今尚未完全清楚,目前公认乳腺癌的发生和发展是一个复杂、多步骤的过程,与许多基因和蛋白的表达相关,包括原癌基因的激活、抑癌基因的突变和丢失等。近年来,对乳腺癌发生、发展中的基因改变和功能分析一直是该领域研究的热点。解聚素-金属蛋白酶(a disintegrin and metalloproteinases,ADAMs)是近年来发现的一类具有多种功能的细胞膜表面糖蛋白家族,大约有800-1200个氨基酸残基组成,通过影响表皮细胞生长因子受体(pidermal Growth Factor Receptor,EGFR )信号转导等多种途径在肿瘤靶向治疗中发挥重要作用。解聚素-金属蛋白酶17(a disintegrin and metalloproteinase 17,ADAM17)是ADAM蛋白家族成员之一,又名肿瘤坏死因子转化酶(Tumor necrosis factor converting enzyme, TACE),已发现其在多种肿瘤中高表达,对肿瘤的发生、发展起重要作用。我们课题组前期的实验结果也显示ADAM17在乳腺纤维腺瘤中呈低表达,而在乳腺癌中呈高表达。
RNA干扰(RNA interference,RNAi)技术是近几年来出现的新的基因沉默技术,相较于反义寡核苷酸技术具有高效、特异、低毒和发挥效应快等优点,在基因阻断方面逐渐替代传统的反义技术。我们通过RNAi使ADAM17基因沉默,观察ADAM17 mRNA表达水平的改变及其对MCF-7人乳腺癌细胞增殖的影响,从而揭示ADAM17与肿瘤细胞增殖的关系,为乳腺癌靶基因治疗提供一些理论及实验依据。
方法:本实验以MCF-7人乳腺癌细胞株作为研究对象,观察
ADAM17-siRNA转染MCF-7人乳腺癌细胞后对其增殖的影响;利用脂质体介导ADAM17- siRNA转染MCF-7细胞,采用实时荧光聚合酶链反应(Realtime polymerase chain reaction,RT-PCR)检测ADAM17在mRNA转录水平的表达水平;通过绘制细胞生长曲线法、MTT法检测细胞增殖活性;以流式细胞仪检测细胞周期。
结果:
1. RT-PCR结果显示利用脂质体介导ADAM17-siRNA转染MCF-7细胞后,转染组ADAM17 mRNA表达水平较对照组显著下调,差异具有统计学意义(p<0.05)。
2. MTT法及细胞生长曲线显示转染ADAM17-siRNA组的MCF-7细胞增殖能力较对照组显著降低,差异具有统计学意义(p<0.05)。
3.流式细胞术检测结果显示,转染组MCF-7细胞生长出现抑制,停滞在G0/Gl期,较对照组显著增加,差异具有统计学意义(p<0.05)。
结论:
通过脂质体转染法将ADAM17-siRNA转染入MCF-7人乳腺癌细胞后,MCF-7细胞ADAM17 mRNA表达水平明显下调,细胞停滞于G0/G1期,细胞增殖能力明显下降。提示ADAM17在乳腺癌细胞异常增殖中起到重要作用,有可能成为乳腺癌基因治疗的侯选基因,具有潜在的临床应用前景。
Objective
Breast tumor is the most common malignant tumor in female, its incidence is increasing in recent years. For now, its pathogenic mechanism is not clear but it is considered that it results from multiple actions among many factors in coordination with many genes and protein high expression in breast cancer, including oncogene active and antioncogene defective. In recent years, More and more researchers have attracted much attention in the field of genetic changes and function analysis in the development and prognosis of breast cancer. It has been recently discovered that A Disintegrin And Metalloproteinase is of the same category of multifunctional cell membranecell protein family, which is made up of 800 to 1200 amino acid. ADAM, as a new target, may play a valuable role in tumor target therapy by affecting transduction of EGRF signal. ADAM17, TACE, is one of the members of ADAMs, which has been observed high expression in multiple tumors, and played a significant role in tumor genesis and development by regulating cell cycle. Our published reports further confirmed that ADAM17 protein was observed low expression in fibroadenoma, but high expression in breast cancer tissue.
RNAi (RNA interference) technology has been commonly used in the approach of silencing gene expression recently. Compared with antisense oligonucleotides, RNA interference technology has following advantages: higher efficiency, better specificity, lower toxicity, quicker effect, as well as more convenient manipulation. So it will gradually substitute traditional antisense technology in gene block.
The study was designed to investigate the effect of ADAM17-si- RNA on the growth and proliferation of MCF-7 breast cancer cell line by making ADAM17 gene silence with siRNA. The research is expected to reveal the relationship between ADAM17 and cell cycle regulation and establish the theory basis for target gene therapy.
Methods
RNAi technology was used to observe its inhibitory effect on the growth of human breast cancer MCF-7 cells. siRNA targeting ADAM17 was transfected into MCF-7 cells mediated by oligofectamine. ADAM17 mRNA expression were detected by RT-PCR after transfection. The phenotypic change of MCF-7 cells including proliferation ability and cell cycle after RNAi trasfection was studied by MTT assay and flow cytometry.
Results
RT-PCR revealed significantly lowered ADAM17 expression at mRNA level in transfected MCF-7 cells. MCF-7 cells exhibited a significantly lower growth rate after transfection as shown by cell growth curve and MTT assay and flow cytometry analysis.
Conclusions
Using RNAi technology,siRNA targeting ADAM17 mediated by oligofectamine efficiently knocks down the expression of ADAM17 in human breast cancer MCF-7 cells, results in decrease of cell proliferation activity, arrests cell cycle. RNAi is a new gene silencing technology with high efficiency, ADAM17 can be the candidate genes for gene therapy of breast cancer, which will have potential application prospects in clinics.
乳腺癌是女性最常见的恶性肿瘤之一,近年来其发病率逐年上升。其具体发生机制至今尚未完全清楚,目前公认乳腺癌的发生和发展是一个复杂、多步骤的过程,与许多基因和蛋白的表达相关,包括原癌基因的激活、抑癌基因的突变和丢失等。近年来,对乳腺癌发生、发展中的基因改变和功能分析一直是该领域研究的热点。解聚素-金属蛋白酶(a disintegrin and metalloproteinases,ADAMs)是近年来发现的一类具有多种功能的细胞膜表面糖蛋白家族,大约有800-1200个氨基酸残基组成,通过影响表皮细胞生长因子受体(pidermal Growth Factor Receptor,EGFR )信号转导等多种途径在肿瘤靶向治疗中发挥重要作用。解聚素-金属蛋白酶17(a disintegrin and metalloproteinase 17,ADAM17)是ADAM蛋白家族成员之一,又名肿瘤坏死因子转化酶(Tumor necrosis factor converting enzyme, TACE),已发现其在多种肿瘤中高表达,对肿瘤的发生、发展起重要作用。我们课题组前期的实验结果也显示ADAM17在乳腺纤维腺瘤中呈低表达,而在乳腺癌中呈高表达。
RNA干扰(RNA interference,RNAi)技术是近几年来出现的新的基因沉默技术,相较于反义寡核苷酸技术具有高效、特异、低毒和发挥效应快等优点,在基因阻断方面逐渐替代传统的反义技术。我们通过RNAi使ADAM17基因沉默,观察ADAM17 mRNA表达水平的改变及其对MCF-7人乳腺癌细胞增殖的影响,从而揭示ADAM17与肿瘤细胞增殖的关系,为乳腺癌靶基因治疗提供一些理论及实验依据。
方法:本实验以MCF-7人乳腺癌细胞株作为研究对象,观察
ADAM17-siRNA转染MCF-7人乳腺癌细胞后对其增殖的影响;利用脂质体介导ADAM17- siRNA转染MCF-7细胞,采用实时荧光聚合酶链反应(Realtime polymerase chain reaction,RT-PCR)检测ADAM17在mRNA转录水平的表达水平;通过绘制细胞生长曲线法、MTT法检测细胞增殖活性;以流式细胞仪检测细胞周期。
结果:
1. RT-PCR结果显示利用脂质体介导ADAM17-siRNA转染MCF-7细胞后,转染组ADAM17 mRNA表达水平较对照组显著下调,差异具有统计学意义(p<0.05)。
2. MTT法及细胞生长曲线显示转染ADAM17-siRNA组的MCF-7细胞增殖能力较对照组显著降低,差异具有统计学意义(p<0.05)。
3.流式细胞术检测结果显示,转染组MCF-7细胞生长出现抑制,停滞在G0/Gl期,较对照组显著增加,差异具有统计学意义(p<0.05)。
结论:
通过脂质体转染法将ADAM17-siRNA转染入MCF-7人乳腺癌细胞后,MCF-7细胞ADAM17 mRNA表达水平明显下调,细胞停滞于G0/G1期,细胞增殖能力明显下降。提示ADAM17在乳腺癌细胞异常增殖中起到重要作用,有可能成为乳腺癌基因治疗的侯选基因,具有潜在的临床应用前景。
Objective
Breast tumor is the most common malignant tumor in female, its incidence is increasing in recent years. For now, its pathogenic mechanism is not clear but it is considered that it results from multiple actions among many factors in coordination with many genes and protein high expression in breast cancer, including oncogene active and antioncogene defective. In recent years, More and more researchers have attracted much attention in the field of genetic changes and function analysis in the development and prognosis of breast cancer. It has been recently discovered that A Disintegrin And Metalloproteinase is of the same category of multifunctional cell membranecell protein family, which is made up of 800 to 1200 amino acid. ADAM, as a new target, may play a valuable role in tumor target therapy by affecting transduction of EGRF signal. ADAM17, TACE, is one of the members of ADAMs, which has been observed high expression in multiple tumors, and played a significant role in tumor genesis and development by regulating cell cycle. Our published reports further confirmed that ADAM17 protein was observed low expression in fibroadenoma, but high expression in breast cancer tissue.
RNAi (RNA interference) technology has been commonly used in the approach of silencing gene expression recently. Compared with antisense oligonucleotides, RNA interference technology has following advantages: higher efficiency, better specificity, lower toxicity, quicker effect, as well as more convenient manipulation. So it will gradually substitute traditional antisense technology in gene block.
The study was designed to investigate the effect of ADAM17-si- RNA on the growth and proliferation of MCF-7 breast cancer cell line by making ADAM17 gene silence with siRNA. The research is expected to reveal the relationship between ADAM17 and cell cycle regulation and establish the theory basis for target gene therapy.
Methods
RNAi technology was used to observe its inhibitory effect on the growth of human breast cancer MCF-7 cells. siRNA targeting ADAM17 was transfected into MCF-7 cells mediated by oligofectamine. ADAM17 mRNA expression were detected by RT-PCR after transfection. The phenotypic change of MCF-7 cells including proliferation ability and cell cycle after RNAi trasfection was studied by MTT assay and flow cytometry.
Results
RT-PCR revealed significantly lowered ADAM17 expression at mRNA level in transfected MCF-7 cells. MCF-7 cells exhibited a significantly lower growth rate after transfection as shown by cell growth curve and MTT assay and flow cytometry analysis.
Conclusions
Using RNAi technology,siRNA targeting ADAM17 mediated by oligofectamine efficiently knocks down the expression of ADAM17 in human breast cancer MCF-7 cells, results in decrease of cell proliferation activity, arrests cell cycle. RNAi is a new gene silencing technology with high efficiency, ADAM17 can be the candidate genes for gene therapy of breast cancer, which will have potential application prospects in clinics.
引文
[1]史淑红,刘英丽,教伟等.乳腺癌中Livin的表达与癌细胞凋亡相关性的研究[J].现代肿瘤医学,2009,17(12):2320-2323.
[2]Teschendorff AE, Caldas C. The breast cancer somatic‘muta-ome’: tackling the complexity [J]. Breast Cancer Res, 2009, 11(2) : 301.
[3]左文述,徐忠法,刘奇等.现代乳腺肿瘤学[M].济南:山东科学技术出版社,1995:13-15.
[4]沈镇宙,邵志敏.乳腺肿瘤学[M].上海:上海科学技术出版社, 2005.5.
[5]Mochizuki S,Okada Y.ADAMs in cancer cell proliferation and progression[J].Cancer Sci,2007,98(5):621-628.
[6]Blobel CP, Myles DG, Primakoff P, et al. Proteolytic processing of a protein involved in sperm-egg fusion correlates with acquisition of fertilization competence[J]. J Cell Biol, 1990, 111(1):69-78.
[7]Black RA,Rauch CT,Kozlosky CJ,et al.A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells [J]. Nature,1997, 385(6618):729-733.
[8]Kubota Y,Sano M,Goda S,et a1.The conserved oligomeric Golgi complex acts in organ morphogenesis via glycosylation of an ADAM protease in C.elegans[J].Development,2006,133(2):263-273.
[9]Wheeler DL,Ness KJ,Oberley TD,et a1.Protein kinase cepsilon is linked to 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor-alpha ectodomain shedding and the development of metastatic squamous cell carcinoma in protein kinase cepsilon transgenic mice[J].Cancer Res,2003,63(19):6547-6555.
[10]Gschwind A, Hart S, Fischer OM, et al. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells[J]. EMBO J, 2003, 22 (10): 2411-2421.
[11]Blanchot-Jossic F,Jarry A, Masson D, et a1.Up-regulated expression of ADAM17 in human colon carcinoma:co-expression with EGFR in neoplastic and endothelial cells[J].J Pathol,2005,207(2):156-163.
[12]McGowan PM, Ryan BM, Hill AD, et al. ADAM-17 expression in breast cancer correlates with variables of tumor progression. ClinCancer Res.2007 13(8):2335-2343.
[13]韩旭,杨星飞,张雪鹏等.ADAM17在乳腺癌组织中的表达及意义[J].现代中西医结合杂志,2010,19(20):2486-2488.
[14]Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells[J]. Nature, 2001, 411(6836):494-498.
[15]Fire A,Xu S,Montgomery MK,et al.Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans[J]. Nature,1998,391(6669):806-811.
[16]Hannon GJ.RNA interference[J].Nature,2002,418(6893):38-39.
[17]Parry DH,Xu J,Ruvkun G.A whole-genome RNAi Screen for C. elegans miRNA pathway genes [J].Curr Biol,2007,17(23):2013-2022.
[18]Bohula EA,Salisbury AJ,Sohail M,et al.The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor(IGF1R) is influenced by secondary structure in the IGF1R transcript[J].J Bio Chem,2003,278(18):l599l-15997.
[19]Miyagishi M,Taira K.U6 promoter-driven siRNAs with four uridine 3’overhangs efficiently suppress targeted gene expression in mammalian cells[J].Nat Biotechnol,2002,19(2):497-500.
[20]Castanotto D,Li HT,Rossi JJ.Functional siRNA expression from transfected PCR products[J].RNA,2002,8(4):1454-1460.
[21]Kumar R,Conklin DS,Mittal V.High-throughput selection of efective RNAi probes for gene silencing[J].Genome Res, 2003, 13(8): 2333- 2340.
[22]Sui C,SoohooC,Affarel B,et al.A DNA vector-based RNAi technology to suppress gene expression in mammalian cells[J].Proc Natl Acad Sci USA,2002,99(80):5515-5520.
[23]Lingor P,Michel U,Scholl U,et a1.Transfection of”naked”siRNA results in endosomal uptake and metabolic impairment in cultured neurons[J].Biochem Biophys Res,2004,315(4):1126-1133.
[24]Elbashir SM,Harborth J,Lendeckel W,et a1.Duplexes of 2 1-nucleotide RNAs mediate RNA interference in cultured mammalian cells[J].Nature,2001,411(6836):494-498.
[25]马雷,吴爱国,纪术峰等.短发夹RNA沉默S100A4基因对乳腺癌MCF-7细胞体外增殖和迁移力的抑制[J].肿瘤防治研究,2010,37(4):402-406.
[26]马杰,李继见,李洋.siRNA沉默FAK基因表达对乳腺癌MCF-7细胞生物学特性的影响[J].重庆医学大学学报,2009,34(5):542-546.
[27]Sancéau J,Ttuchet S, Bauvois B.Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing’s sarcoma cells[J].J Bio Chem,2003,278(38),36537-36546.
[28]Hennesy C,Henry JA,May FE,et al.Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis[J].J Natl Cancer Inst,1991,83(4):281-285.
[29]Bundred NJ,Chan K,Anderson NG.Studies of epidermal growth factor receptor inhibition in breast cancer[J].Endocr Relat Cancer,2001, 8(3):183–189.
[30]Garton KJ,Cough PJ,Blobel CP,et al.Tumor necrosis factor-alpha -converting enzyme(ADAM17)mediates the cleavage and shedding of fractalkine(CX3CL1)[J].J Biol Chem, 2001, 276(41): 37993-38001.
[31]Sunnarborg SW,Hinkle CL,Stevenson M,et al.Tumor necrosis factor -converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability[J].J Biol Chem,2000,227:12838-12845.
[32]Gschwind A,Hart S,Fischer OM,et al.TACE cleavage of proam- phiregulin regulates GPCR-induced proliferation and motility of cancer cells[J].EMBO J,2003,22 (10):2411-2421.
[33]Wheeler DL,Ness KJ,Oberley TD,et al.Protein kinase Cepsilon is linked to 12-O-tetradecanoylphorbol-13-acetate-induced tumor necr- osis factor-alpha ectodomain shedding and the development of meta- static squamous cell carcinoma in protein kinase Cepsilon transgenic mice[J].Cancer Res,2003,63:6547-6555.
[34]Franovic A,Robert I,Smith K,et al.Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17[J]. Cancer Res,2006, 66 (16):8083-8090.
[35]McGowan PM,McKiernan E,Bolster F,et al.ADAM-17 predicts adverse outcome in patients with breast cancer[J].AnnOncol,2008,19(6):1075-1081.
[36]Mitsui Y,Mochizuki S,Kodama T,et al.ADAM28 is overexpressed in human breast carcinomas:implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3[J]. Cancer Res,2006,66(20):9913-9920.
[37]Kermy PA,Bissell MJ.Targeting TACE-dependent EGFR ligand shed- ding in breast cancer[J].J Clin Invest,2007,117(2):337-345.
[38]Liu Y,Wang Z,Ji Y,et al.siRNA of ADAM17 gene induces apoptosis,proliferation inhibition and enhances the effects of genistein on HepG2 cells[J]. Journal of Nanjing Medical University,2009,23(2): 127 -131.
[1]杨光华,李甘地.病理学[M].第5版,北京:人民卫生出版社, 2002: 80.
[2]Chambers AF,Matrisian LM.Changing views of the role of matrix me- tallocproteinase in metastasis[J].J Natl Cancer Inst, 1997, 89: 1260- 1270.
[3]Yokota J.Tumor progression and metastasis[J]. Carcinogenesis, 2000,21:497-503.
[4]Becherer JD,Blobel CP.Biochemical properties and functions of mem- brane-anchored metalloprotease-disintegrin proteins (ADAMs)[J]. Curr Top Dev Biol,2003,54:101-123.
[5]Blobel CP.Metalloprotease-disintegrin:links to cell adhesion and cleavage of TNF alpha and Notch[J].Cell,1997,90(4): 589- 593.
[6]Blobel CP,Myles DG,Primakoff P,et a1.Proteolytic processing of a protein involved in sperm-egg fusion correlates with acquisition of fertilization competence[J].J Cell Biol, 1990,111(1):69-78.
[7]Mochizuki S,Okada Y.ADAMs in cancer cell proliferation and progression[J].Cancer Sci,2007,98(5):621-628.
[8]Stone A L,Kroeger M, Sang QX. Structure-function analysis of the ADAM family of disintegrin-like and metalloproteinase -containing Proteins (review) [J].J Protein Chem,1999,18(4): 447- 465.
[9]Bigler D,Takahashi Y,Chen MS,et al.Sequence-specific interaction between the disintegrin domain of mouse ADAM2 (fertilin beta) and murine eggs.Role of the alpha(6) integrin subunit[J].J Biol Chem, 2000,275(16):11576-11584·
[10]Raymond E,Faivre S,Armand JP.Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy[J]. Durgs,2000, 60 (1):15-23.
[11]Sahin U, Weskamp G, Kelly K,et al.Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands [J].J Cell Bio, 2004,164(5):769-779.
[12]Garrett TP,McKern NM,Lou M,et al.Crystal structure of a truncated Epidermal growth factor receptor extracellular domain bound totransforming growth factor alpha[J].Cell, 2002,110(6):763-773.
[13] Borrell-Pagès M,Rojo F,Albanell J,et a1.TACE is required for the activation of the EGFR by TGF-alpha in tumors[J]. EMBO J,2003, 22(5):1114-1124.
[14]Maretzky T,Reiss K,Ludwig A,et al.ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration,and beta-catenin translocation[J].Proc Natl Acad Sci USA,2005, 102(26): 9182-9187.
[15]Kveiborg M,Fr ? hlich C,Albrechtsen R,et al.A role for ADAMl2 in breast tumor progression and stromal ceell apoptosis [J]. Cancer Res,2005,65(11):4754-4761.
[16]0'Shea,McKie N,Buggy Y,et al.Expression of ADAM-9 mRNA and protein in human breast cancer[J].Int J Cancer, 2003, 105 (6): 754-761.
[17]Lendeckel U,Kohl J,Arndt M,et al.Increased expression of ADAM family members in human breast cancer and breast cancer cell lines [J].J Cancer Res Clin Oncol,2005,131(1): 41-48.
[18]Rocks N,Paulissen G,Quesada Calvo F, et al.Expression of a disintergrin and metalloprotease (ADAM and ADAMTS) enzymes in hummn non-small-cell lung carcinomas (NSCLC)[J]. 2006, 94(05): 724-730.
[19]Kuefer R,Day KC,Kleer CG,et al.ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease[J]. Neoplasia, 2006,8(4):319-329.
[20]McGowan PM, McKiernan E, Bolster F, et al. ADAM17 predicts adverse outcome in patients with breast cancer[J].Ann Oncol, 2008,19(6):1075-1081.
[21]韩旭,杨星飞,张雪鹏等.ADAM17在乳腺癌组织中的表达及意义[J].现代中西医结合杂志,2010,19(20):2486-2488.
[22]Costa FF, Verbisck NV, Salim AC, et al.Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors[J]. Oncogene 2004;23(7):1481-1488.
[23]Mitsui Y,Mochizuki S,Kodama T,et al.ADAM28 is overexpressed inhuman breast carcinomas: implications for carcinoma cell proli- feration through cleavage of insulin-like growth factor binding protein-3[J].Cancer Res,2006,66(20):9913-9920.
[24]Ishikawa N,Daigo Y, Yasui W,et al.ADAM8 as a novel serological and histochemical marker for lung cancer[J].Clin Cancer Res,2004, 10(24):8363-8370.
[25]华成,施敏骅.ADAM8、EGFR在非小细胞肺癌中的表达及其相关性[J].癌症,2008,27(8): 874-878.
[26]Shintani Y,Higashiyama S,Ohta M,et al.Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis[J]. Cancer Res,2004,64(12):4190-4196.
[27]Zhang J,Ren H,Yuan P,et al.Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells[J].Cancer Res,2006,66(1): 18-23.
[28]Zhang J,Mao L.siRNA targeting hepatoma-derived growth factor(H- DGF)inhibits growth of non-small cell lung cancer in xenograft mod- els.Tumor Biology 35:Emerging Molecules, Mechanisms, and Models[J]. Proc Amer Assoc Cancer Res, Volume 47, 2006.
[29]祁娟,张军. ADAM9在肺癌组织中的异常表达[J].中国医科大学学报, 2010, 39(8):670-671.
[30]Rocks N,Paulissen G,Quesada CF,et al.Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non- small-cell lung carcinomas(NSCLC)[J]. British Journal of Cancer, 2006,4(5):724 ?730.
[31]Zhou BB,Fridman JS,Liu X, et al.ADAM proteases,ErbB pathways and cancer[J].Expert Opin Investig Drugs, 2005, 14(06):591.
[32]Ohtsuka T, Shiomi T, Shimoda M, et al. ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell pro- liferation and lymphnode metastasis[J]. Int J Cancer, 2006, 118(2): 263-273.
[33]胡春燕,周建华,邓征浩.ADAM23、αvβ3在非小细胞肺癌中的表达及临床意义[J].临床与实验病理学杂志,2010, 26(4): 433- 441.
[34]Mazzocca A,Coppari R,De Franco R,et al.A secreted form of ADA- M9 promotes carcinoma invasion through tumor-stromal interactions [J].Cancer Res,2005,65(11):4728-4738.
[35]Itabashi H,Maesawa C,Oikawa H,el al.AngiotensinⅡand epidermal growthfactor receptor cross-talk mediated by a disintegrin and me- talloprotease accelerates tumor cell proliferation of hepatocellular carcinoma cell lines[J]. Hepa- tol Res,2008,38(6):60l-613.
[36]Le Pabic H,L'Helgoualc'h A,Coutant A. Involvement of the serine/threonine p70S6 kinase in TGF-beta1-induced ADAM12 expression in cultured human hepatic stellate cells[J].J Hepatol,2005, 43(06):1038-1044.
[37]Adam RM, Danciu T, McLellan DL, et al.A nuclear form of the heaprin-binding epidermal growth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma [J].Cancer Res, 2003,63(2):484-490.
[38]Le Pabic H, Bonnier D, Wewer UM, et al.ADAM12 in human liver cancers:TGF-beta-regulated expression in stellate cells is associated with matrix remodeling[J].Hepatology,2003,37(5): 1056-1066.
[39]丁翔,杨连粤,黄耿文等.ADAM17 mRNA在孤立性大肝癌肿的表达及其意义[J].中华肝胆外科杂志,2005,11(8):544-546.
[40]Carl-McGrath S, Lendeckel U, Ebert M, et al. The disintegrin-metal- oproteinases ADAM9,ADAM12 and ADAM15 are upregulated in gastric cancer[J].Int J Oncol,2005,26(01):17-24.
[41] Yoshimura T, Tomita T, Dixon MF, et al. ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori-infected,normal,and neoplastic gastric mucosa[J].J Infect Dis, 2002,185(3):332-340.
[42]Takada H,Imoto I, Tsuda H, et al. ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation[J]. Oncogene, 2005, 24(54):8051-8060.
[43]Mazzocca A, Coppari R, De Franeo R. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal intera-ctions[J].Cancer Res,2005,65(11):4728-4738.
[44]陆熊熊,郑民华,王明亮等.解聚素-金属蛋白酶17在结直肠癌中的表达及其意义[J].外科理论与实践,2008,13(2):153-156.
[45]Blanchot-Jossic F, Jarry A, Masson D, et al. Up-regulated expression of ADAM17 in human colon carcinoma:co-expression with EGFR in neoplastic and endothelial cells[J].J Pathol, 2005,207(2):156-163.
[46]王夫景,张强,于洪亮等.ADAM23基因在结直肠癌中的表达及其意义[J].世界华人消化杂志,2008,16(30):3406-3409.
[47]Peduto L, Reuter VE, Shaffer DR, et al. Critical function for ADAM9 in mouse prostate cancer[J]. Cancer Res,2005,65(20): 9312-9319.
[48]Shigemura K, Sung SY, Knbo H, et al. Reactive oxygen species med- iate androgen receptor-and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells[J]. Prostate,2007,67(7):722-731.
[49]Sung SY, Kubo H, Shigemura K, et al. Oxidative stress induces AD- AM9 protein expression in human prostate cancer cells[J] . Cancer R- es,2006,66(19):9519-9526.
[50]McCulloch DR, Akl P, Samaratunqa H, et al. Expression of the disi- ntegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone,insulin-Like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP[J].Clin Cancer Res, 2004, 10(1):314-323.
[51]Karan D, Lin FC, Bryan M, et al. Expression of ADAMs (a disinteg- rin and metalloproteases) and TIMP-3 (tissue inhibitor of me- talloproteinase-3) in human prostatic adenocarcinomas[J]. Int J Oncol,2003,23(5):1365?1371.
[52]Najy AJ,Day KC,Day ML.ADAMl5 supports prostate cancer metast- asis by modulating tumor cell-endotheliaI cell interaction [J].Cancer Res,2008,68(4):1092-1099.
[53]McCulloch DR,Harvey M,Herington AC.The expression of the AD- AMs proteases in prostate cancer cell lines and their regulation by di- hydrotestosterone[J].Mol Cell Endocrinol,2000,167(1-2): 11-21.
[54]Karan D,Lin FC,Bryan M,et al.Expression of ADAMs ( a disintegrinand metalloproteases) and TIMP-3 ( tissue inhibitor of metalloprotei- nase-3) in human prostatic adenocarcinomas [J].Int J Oncol, 2003,23 (5): 1365-1371.
[55]Roemer A,Schwettmann L,Jung M,et al.Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome[J].Oncol Rep,2004, 11(2): 529-536.
[56]Fr (?) hlich C, Albrechtsen R, Dyrskjot L, et al. Molecular profiling of ADAM12 in human bladder cancer[J].Clin Cancer Res, 2006,12(24): 7359-7368.
[57]Fritzsche FR,Wassermann K,Jung M,et al.ADAM9 is highly express- ed in renal cell cancer and is associated with tumour progression [J]. BMC Cancer,2008,8:179-187.
[58]Wildeboer D,Naus S,Amy Sang QX,et al.Metalloproteinase disintegr- ins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activeties are associa- ted with invasiveness[J].J Neuropathol Exp Neurol,2006, 65(5): 516- 527.
[59]Shintani Y, Higashiyama S, Ohta M, et al.Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis[J].Cancer Res, 2004,64(12):4190-4196.
[60]Kodama T, Ikeda E, Okada A, et al. ADAMl2 is selectively oversxpressed in human glioblastomas and is associated with glioblastom cell proliferation and shedding of heparin-binding epidermal growth factor[J].Am J Pathol. 2004,165(5):1743-1753.
[61]Held-Feindt J,Paredes EB, Bl(?)mer U, et al. Matrix-degrading proteases ADAMTS4 and ADAMTS5 (disintegrins and metalloproteinases with thrombospondin motifs 4 and 5) are expressed in human glioblastomas[J].Int J Cancer,2006,118(1): 55-61.
[62]Valkovskaya N, Kayed H, Felix K, et al. ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer[J].J Cell Mol Med,2007,11(5): 1162-1174.
[63]Yamada D, Ohuchida K, Mizumoto K, et al. Increased expression ofADAM9 and ADAM 15 mRNA in pancreatic cancer[J]. Anticancer Res, 2007,27(02):793-799.
[64]Asayesh A, Alanentalo T, Khoo NK, et al. Developmental expression of metalloproteases ADAM9, 10 and17 becomes restricted to diverg- divergent panereatie compartments[J]. Dev Dyn, 2005,232(4):1105- 1114.
[65]Grutzmann R, Luttges J, Sipos B, et al. ADAM9 expression in pancr- eatic cancer is associated with tumor type and is a prognostic factor in ductal adenocarcinoma[J].Br J Caneer,2004,90(5): 1053- 1058.
[66]Ringel J,Jesnowski R,Moniaux N,et al.Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma[J]. Cancer Res,2006,66(18): 9045-9053.
[67]欧志奇,张岩,于丽等.ADAM19在子宫内膜癌组织中的表达及临床意义[J].北京大学学报,2008,40(2):165-169.
[68]Tanaka Y, Miyamoto S, Suzuki SO, et a1. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer[J].Clin Cancer Res,2005,11(13):4783-4792.
[69]Beck V,Herold H,Benge A,et a1.ADAM 15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion[J].Int J Biochem Cell Biol,2005,37(3):590-603.
[70]Takamune Y,lkebe T,Nagano O,et al.Involvement of NF-kappaB -mediated maturation of ADAM-17 in the invasion of oral squamous cell carcinoma[J].Biochem Biophys Res Commun, 2008,365 (2): 393-398.
[71]Ko SY, Lin SC, Wong YK, et al. Increase of disintergin metal- oprotease 10 (ADAM10) expression in oral squamous cell carcinoma[J]. Cancer Lett, 2007, 245(1-2): 33-43.
[72]陈启,冯吉焕,张莹.分化型甲状腺癌中ADAM9的表达及其与临床病理因素的关系[J].实用癌症杂志, 2010, 25(3): 263-264.
[73]Zigrino P, Mauch C, Fox JW, et al. ADAM9 expression and regulation in human skin melanoma and melanoma cell lines[J]. Int J Cancer, 2005, 116(6): 853-859.
[2]Teschendorff AE, Caldas C. The breast cancer somatic‘muta-ome’: tackling the complexity [J]. Breast Cancer Res, 2009, 11(2) : 301.
[3]左文述,徐忠法,刘奇等.现代乳腺肿瘤学[M].济南:山东科学技术出版社,1995:13-15.
[4]沈镇宙,邵志敏.乳腺肿瘤学[M].上海:上海科学技术出版社, 2005.5.
[5]Mochizuki S,Okada Y.ADAMs in cancer cell proliferation and progression[J].Cancer Sci,2007,98(5):621-628.
[6]Blobel CP, Myles DG, Primakoff P, et al. Proteolytic processing of a protein involved in sperm-egg fusion correlates with acquisition of fertilization competence[J]. J Cell Biol, 1990, 111(1):69-78.
[7]Black RA,Rauch CT,Kozlosky CJ,et al.A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells [J]. Nature,1997, 385(6618):729-733.
[8]Kubota Y,Sano M,Goda S,et a1.The conserved oligomeric Golgi complex acts in organ morphogenesis via glycosylation of an ADAM protease in C.elegans[J].Development,2006,133(2):263-273.
[9]Wheeler DL,Ness KJ,Oberley TD,et a1.Protein kinase cepsilon is linked to 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor-alpha ectodomain shedding and the development of metastatic squamous cell carcinoma in protein kinase cepsilon transgenic mice[J].Cancer Res,2003,63(19):6547-6555.
[10]Gschwind A, Hart S, Fischer OM, et al. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells[J]. EMBO J, 2003, 22 (10): 2411-2421.
[11]Blanchot-Jossic F,Jarry A, Masson D, et a1.Up-regulated expression of ADAM17 in human colon carcinoma:co-expression with EGFR in neoplastic and endothelial cells[J].J Pathol,2005,207(2):156-163.
[12]McGowan PM, Ryan BM, Hill AD, et al. ADAM-17 expression in breast cancer correlates with variables of tumor progression. ClinCancer Res.2007 13(8):2335-2343.
[13]韩旭,杨星飞,张雪鹏等.ADAM17在乳腺癌组织中的表达及意义[J].现代中西医结合杂志,2010,19(20):2486-2488.
[14]Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells[J]. Nature, 2001, 411(6836):494-498.
[15]Fire A,Xu S,Montgomery MK,et al.Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans[J]. Nature,1998,391(6669):806-811.
[16]Hannon GJ.RNA interference[J].Nature,2002,418(6893):38-39.
[17]Parry DH,Xu J,Ruvkun G.A whole-genome RNAi Screen for C. elegans miRNA pathway genes [J].Curr Biol,2007,17(23):2013-2022.
[18]Bohula EA,Salisbury AJ,Sohail M,et al.The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor(IGF1R) is influenced by secondary structure in the IGF1R transcript[J].J Bio Chem,2003,278(18):l599l-15997.
[19]Miyagishi M,Taira K.U6 promoter-driven siRNAs with four uridine 3’overhangs efficiently suppress targeted gene expression in mammalian cells[J].Nat Biotechnol,2002,19(2):497-500.
[20]Castanotto D,Li HT,Rossi JJ.Functional siRNA expression from transfected PCR products[J].RNA,2002,8(4):1454-1460.
[21]Kumar R,Conklin DS,Mittal V.High-throughput selection of efective RNAi probes for gene silencing[J].Genome Res, 2003, 13(8): 2333- 2340.
[22]Sui C,SoohooC,Affarel B,et al.A DNA vector-based RNAi technology to suppress gene expression in mammalian cells[J].Proc Natl Acad Sci USA,2002,99(80):5515-5520.
[23]Lingor P,Michel U,Scholl U,et a1.Transfection of”naked”siRNA results in endosomal uptake and metabolic impairment in cultured neurons[J].Biochem Biophys Res,2004,315(4):1126-1133.
[24]Elbashir SM,Harborth J,Lendeckel W,et a1.Duplexes of 2 1-nucleotide RNAs mediate RNA interference in cultured mammalian cells[J].Nature,2001,411(6836):494-498.
[25]马雷,吴爱国,纪术峰等.短发夹RNA沉默S100A4基因对乳腺癌MCF-7细胞体外增殖和迁移力的抑制[J].肿瘤防治研究,2010,37(4):402-406.
[26]马杰,李继见,李洋.siRNA沉默FAK基因表达对乳腺癌MCF-7细胞生物学特性的影响[J].重庆医学大学学报,2009,34(5):542-546.
[27]Sancéau J,Ttuchet S, Bauvois B.Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing’s sarcoma cells[J].J Bio Chem,2003,278(38),36537-36546.
[28]Hennesy C,Henry JA,May FE,et al.Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis[J].J Natl Cancer Inst,1991,83(4):281-285.
[29]Bundred NJ,Chan K,Anderson NG.Studies of epidermal growth factor receptor inhibition in breast cancer[J].Endocr Relat Cancer,2001, 8(3):183–189.
[30]Garton KJ,Cough PJ,Blobel CP,et al.Tumor necrosis factor-alpha -converting enzyme(ADAM17)mediates the cleavage and shedding of fractalkine(CX3CL1)[J].J Biol Chem, 2001, 276(41): 37993-38001.
[31]Sunnarborg SW,Hinkle CL,Stevenson M,et al.Tumor necrosis factor -converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability[J].J Biol Chem,2000,227:12838-12845.
[32]Gschwind A,Hart S,Fischer OM,et al.TACE cleavage of proam- phiregulin regulates GPCR-induced proliferation and motility of cancer cells[J].EMBO J,2003,22 (10):2411-2421.
[33]Wheeler DL,Ness KJ,Oberley TD,et al.Protein kinase Cepsilon is linked to 12-O-tetradecanoylphorbol-13-acetate-induced tumor necr- osis factor-alpha ectodomain shedding and the development of meta- static squamous cell carcinoma in protein kinase Cepsilon transgenic mice[J].Cancer Res,2003,63:6547-6555.
[34]Franovic A,Robert I,Smith K,et al.Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17[J]. Cancer Res,2006, 66 (16):8083-8090.
[35]McGowan PM,McKiernan E,Bolster F,et al.ADAM-17 predicts adverse outcome in patients with breast cancer[J].AnnOncol,2008,19(6):1075-1081.
[36]Mitsui Y,Mochizuki S,Kodama T,et al.ADAM28 is overexpressed in human breast carcinomas:implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3[J]. Cancer Res,2006,66(20):9913-9920.
[37]Kermy PA,Bissell MJ.Targeting TACE-dependent EGFR ligand shed- ding in breast cancer[J].J Clin Invest,2007,117(2):337-345.
[38]Liu Y,Wang Z,Ji Y,et al.siRNA of ADAM17 gene induces apoptosis,proliferation inhibition and enhances the effects of genistein on HepG2 cells[J]. Journal of Nanjing Medical University,2009,23(2): 127 -131.
[1]杨光华,李甘地.病理学[M].第5版,北京:人民卫生出版社, 2002: 80.
[2]Chambers AF,Matrisian LM.Changing views of the role of matrix me- tallocproteinase in metastasis[J].J Natl Cancer Inst, 1997, 89: 1260- 1270.
[3]Yokota J.Tumor progression and metastasis[J]. Carcinogenesis, 2000,21:497-503.
[4]Becherer JD,Blobel CP.Biochemical properties and functions of mem- brane-anchored metalloprotease-disintegrin proteins (ADAMs)[J]. Curr Top Dev Biol,2003,54:101-123.
[5]Blobel CP.Metalloprotease-disintegrin:links to cell adhesion and cleavage of TNF alpha and Notch[J].Cell,1997,90(4): 589- 593.
[6]Blobel CP,Myles DG,Primakoff P,et a1.Proteolytic processing of a protein involved in sperm-egg fusion correlates with acquisition of fertilization competence[J].J Cell Biol, 1990,111(1):69-78.
[7]Mochizuki S,Okada Y.ADAMs in cancer cell proliferation and progression[J].Cancer Sci,2007,98(5):621-628.
[8]Stone A L,Kroeger M, Sang QX. Structure-function analysis of the ADAM family of disintegrin-like and metalloproteinase -containing Proteins (review) [J].J Protein Chem,1999,18(4): 447- 465.
[9]Bigler D,Takahashi Y,Chen MS,et al.Sequence-specific interaction between the disintegrin domain of mouse ADAM2 (fertilin beta) and murine eggs.Role of the alpha(6) integrin subunit[J].J Biol Chem, 2000,275(16):11576-11584·
[10]Raymond E,Faivre S,Armand JP.Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy[J]. Durgs,2000, 60 (1):15-23.
[11]Sahin U, Weskamp G, Kelly K,et al.Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands [J].J Cell Bio, 2004,164(5):769-779.
[12]Garrett TP,McKern NM,Lou M,et al.Crystal structure of a truncated Epidermal growth factor receptor extracellular domain bound totransforming growth factor alpha[J].Cell, 2002,110(6):763-773.
[13] Borrell-Pagès M,Rojo F,Albanell J,et a1.TACE is required for the activation of the EGFR by TGF-alpha in tumors[J]. EMBO J,2003, 22(5):1114-1124.
[14]Maretzky T,Reiss K,Ludwig A,et al.ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration,and beta-catenin translocation[J].Proc Natl Acad Sci USA,2005, 102(26): 9182-9187.
[15]Kveiborg M,Fr ? hlich C,Albrechtsen R,et al.A role for ADAMl2 in breast tumor progression and stromal ceell apoptosis [J]. Cancer Res,2005,65(11):4754-4761.
[16]0'Shea,McKie N,Buggy Y,et al.Expression of ADAM-9 mRNA and protein in human breast cancer[J].Int J Cancer, 2003, 105 (6): 754-761.
[17]Lendeckel U,Kohl J,Arndt M,et al.Increased expression of ADAM family members in human breast cancer and breast cancer cell lines [J].J Cancer Res Clin Oncol,2005,131(1): 41-48.
[18]Rocks N,Paulissen G,Quesada Calvo F, et al.Expression of a disintergrin and metalloprotease (ADAM and ADAMTS) enzymes in hummn non-small-cell lung carcinomas (NSCLC)[J]. 2006, 94(05): 724-730.
[19]Kuefer R,Day KC,Kleer CG,et al.ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease[J]. Neoplasia, 2006,8(4):319-329.
[20]McGowan PM, McKiernan E, Bolster F, et al. ADAM17 predicts adverse outcome in patients with breast cancer[J].Ann Oncol, 2008,19(6):1075-1081.
[21]韩旭,杨星飞,张雪鹏等.ADAM17在乳腺癌组织中的表达及意义[J].现代中西医结合杂志,2010,19(20):2486-2488.
[22]Costa FF, Verbisck NV, Salim AC, et al.Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors[J]. Oncogene 2004;23(7):1481-1488.
[23]Mitsui Y,Mochizuki S,Kodama T,et al.ADAM28 is overexpressed inhuman breast carcinomas: implications for carcinoma cell proli- feration through cleavage of insulin-like growth factor binding protein-3[J].Cancer Res,2006,66(20):9913-9920.
[24]Ishikawa N,Daigo Y, Yasui W,et al.ADAM8 as a novel serological and histochemical marker for lung cancer[J].Clin Cancer Res,2004, 10(24):8363-8370.
[25]华成,施敏骅.ADAM8、EGFR在非小细胞肺癌中的表达及其相关性[J].癌症,2008,27(8): 874-878.
[26]Shintani Y,Higashiyama S,Ohta M,et al.Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis[J]. Cancer Res,2004,64(12):4190-4196.
[27]Zhang J,Ren H,Yuan P,et al.Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells[J].Cancer Res,2006,66(1): 18-23.
[28]Zhang J,Mao L.siRNA targeting hepatoma-derived growth factor(H- DGF)inhibits growth of non-small cell lung cancer in xenograft mod- els.Tumor Biology 35:Emerging Molecules, Mechanisms, and Models[J]. Proc Amer Assoc Cancer Res, Volume 47, 2006.
[29]祁娟,张军. ADAM9在肺癌组织中的异常表达[J].中国医科大学学报, 2010, 39(8):670-671.
[30]Rocks N,Paulissen G,Quesada CF,et al.Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non- small-cell lung carcinomas(NSCLC)[J]. British Journal of Cancer, 2006,4(5):724 ?730.
[31]Zhou BB,Fridman JS,Liu X, et al.ADAM proteases,ErbB pathways and cancer[J].Expert Opin Investig Drugs, 2005, 14(06):591.
[32]Ohtsuka T, Shiomi T, Shimoda M, et al. ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell pro- liferation and lymphnode metastasis[J]. Int J Cancer, 2006, 118(2): 263-273.
[33]胡春燕,周建华,邓征浩.ADAM23、αvβ3在非小细胞肺癌中的表达及临床意义[J].临床与实验病理学杂志,2010, 26(4): 433- 441.
[34]Mazzocca A,Coppari R,De Franco R,et al.A secreted form of ADA- M9 promotes carcinoma invasion through tumor-stromal interactions [J].Cancer Res,2005,65(11):4728-4738.
[35]Itabashi H,Maesawa C,Oikawa H,el al.AngiotensinⅡand epidermal growthfactor receptor cross-talk mediated by a disintegrin and me- talloprotease accelerates tumor cell proliferation of hepatocellular carcinoma cell lines[J]. Hepa- tol Res,2008,38(6):60l-613.
[36]Le Pabic H,L'Helgoualc'h A,Coutant A. Involvement of the serine/threonine p70S6 kinase in TGF-beta1-induced ADAM12 expression in cultured human hepatic stellate cells[J].J Hepatol,2005, 43(06):1038-1044.
[37]Adam RM, Danciu T, McLellan DL, et al.A nuclear form of the heaprin-binding epidermal growth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma [J].Cancer Res, 2003,63(2):484-490.
[38]Le Pabic H, Bonnier D, Wewer UM, et al.ADAM12 in human liver cancers:TGF-beta-regulated expression in stellate cells is associated with matrix remodeling[J].Hepatology,2003,37(5): 1056-1066.
[39]丁翔,杨连粤,黄耿文等.ADAM17 mRNA在孤立性大肝癌肿的表达及其意义[J].中华肝胆外科杂志,2005,11(8):544-546.
[40]Carl-McGrath S, Lendeckel U, Ebert M, et al. The disintegrin-metal- oproteinases ADAM9,ADAM12 and ADAM15 are upregulated in gastric cancer[J].Int J Oncol,2005,26(01):17-24.
[41] Yoshimura T, Tomita T, Dixon MF, et al. ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori-infected,normal,and neoplastic gastric mucosa[J].J Infect Dis, 2002,185(3):332-340.
[42]Takada H,Imoto I, Tsuda H, et al. ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation[J]. Oncogene, 2005, 24(54):8051-8060.
[43]Mazzocca A, Coppari R, De Franeo R. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal intera-ctions[J].Cancer Res,2005,65(11):4728-4738.
[44]陆熊熊,郑民华,王明亮等.解聚素-金属蛋白酶17在结直肠癌中的表达及其意义[J].外科理论与实践,2008,13(2):153-156.
[45]Blanchot-Jossic F, Jarry A, Masson D, et al. Up-regulated expression of ADAM17 in human colon carcinoma:co-expression with EGFR in neoplastic and endothelial cells[J].J Pathol, 2005,207(2):156-163.
[46]王夫景,张强,于洪亮等.ADAM23基因在结直肠癌中的表达及其意义[J].世界华人消化杂志,2008,16(30):3406-3409.
[47]Peduto L, Reuter VE, Shaffer DR, et al. Critical function for ADAM9 in mouse prostate cancer[J]. Cancer Res,2005,65(20): 9312-9319.
[48]Shigemura K, Sung SY, Knbo H, et al. Reactive oxygen species med- iate androgen receptor-and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells[J]. Prostate,2007,67(7):722-731.
[49]Sung SY, Kubo H, Shigemura K, et al. Oxidative stress induces AD- AM9 protein expression in human prostate cancer cells[J] . Cancer R- es,2006,66(19):9519-9526.
[50]McCulloch DR, Akl P, Samaratunqa H, et al. Expression of the disi- ntegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone,insulin-Like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP[J].Clin Cancer Res, 2004, 10(1):314-323.
[51]Karan D, Lin FC, Bryan M, et al. Expression of ADAMs (a disinteg- rin and metalloproteases) and TIMP-3 (tissue inhibitor of me- talloproteinase-3) in human prostatic adenocarcinomas[J]. Int J Oncol,2003,23(5):1365?1371.
[52]Najy AJ,Day KC,Day ML.ADAMl5 supports prostate cancer metast- asis by modulating tumor cell-endotheliaI cell interaction [J].Cancer Res,2008,68(4):1092-1099.
[53]McCulloch DR,Harvey M,Herington AC.The expression of the AD- AMs proteases in prostate cancer cell lines and their regulation by di- hydrotestosterone[J].Mol Cell Endocrinol,2000,167(1-2): 11-21.
[54]Karan D,Lin FC,Bryan M,et al.Expression of ADAMs ( a disintegrinand metalloproteases) and TIMP-3 ( tissue inhibitor of metalloprotei- nase-3) in human prostatic adenocarcinomas [J].Int J Oncol, 2003,23 (5): 1365-1371.
[55]Roemer A,Schwettmann L,Jung M,et al.Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome[J].Oncol Rep,2004, 11(2): 529-536.
[56]Fr (?) hlich C, Albrechtsen R, Dyrskjot L, et al. Molecular profiling of ADAM12 in human bladder cancer[J].Clin Cancer Res, 2006,12(24): 7359-7368.
[57]Fritzsche FR,Wassermann K,Jung M,et al.ADAM9 is highly express- ed in renal cell cancer and is associated with tumour progression [J]. BMC Cancer,2008,8:179-187.
[58]Wildeboer D,Naus S,Amy Sang QX,et al.Metalloproteinase disintegr- ins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activeties are associa- ted with invasiveness[J].J Neuropathol Exp Neurol,2006, 65(5): 516- 527.
[59]Shintani Y, Higashiyama S, Ohta M, et al.Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis[J].Cancer Res, 2004,64(12):4190-4196.
[60]Kodama T, Ikeda E, Okada A, et al. ADAMl2 is selectively oversxpressed in human glioblastomas and is associated with glioblastom cell proliferation and shedding of heparin-binding epidermal growth factor[J].Am J Pathol. 2004,165(5):1743-1753.
[61]Held-Feindt J,Paredes EB, Bl(?)mer U, et al. Matrix-degrading proteases ADAMTS4 and ADAMTS5 (disintegrins and metalloproteinases with thrombospondin motifs 4 and 5) are expressed in human glioblastomas[J].Int J Cancer,2006,118(1): 55-61.
[62]Valkovskaya N, Kayed H, Felix K, et al. ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer[J].J Cell Mol Med,2007,11(5): 1162-1174.
[63]Yamada D, Ohuchida K, Mizumoto K, et al. Increased expression ofADAM9 and ADAM 15 mRNA in pancreatic cancer[J]. Anticancer Res, 2007,27(02):793-799.
[64]Asayesh A, Alanentalo T, Khoo NK, et al. Developmental expression of metalloproteases ADAM9, 10 and17 becomes restricted to diverg- divergent panereatie compartments[J]. Dev Dyn, 2005,232(4):1105- 1114.
[65]Grutzmann R, Luttges J, Sipos B, et al. ADAM9 expression in pancr- eatic cancer is associated with tumor type and is a prognostic factor in ductal adenocarcinoma[J].Br J Caneer,2004,90(5): 1053- 1058.
[66]Ringel J,Jesnowski R,Moniaux N,et al.Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma[J]. Cancer Res,2006,66(18): 9045-9053.
[67]欧志奇,张岩,于丽等.ADAM19在子宫内膜癌组织中的表达及临床意义[J].北京大学学报,2008,40(2):165-169.
[68]Tanaka Y, Miyamoto S, Suzuki SO, et a1. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer[J].Clin Cancer Res,2005,11(13):4783-4792.
[69]Beck V,Herold H,Benge A,et a1.ADAM 15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion[J].Int J Biochem Cell Biol,2005,37(3):590-603.
[70]Takamune Y,lkebe T,Nagano O,et al.Involvement of NF-kappaB -mediated maturation of ADAM-17 in the invasion of oral squamous cell carcinoma[J].Biochem Biophys Res Commun, 2008,365 (2): 393-398.
[71]Ko SY, Lin SC, Wong YK, et al. Increase of disintergin metal- oprotease 10 (ADAM10) expression in oral squamous cell carcinoma[J]. Cancer Lett, 2007, 245(1-2): 33-43.
[72]陈启,冯吉焕,张莹.分化型甲状腺癌中ADAM9的表达及其与临床病理因素的关系[J].实用癌症杂志, 2010, 25(3): 263-264.
[73]Zigrino P, Mauch C, Fox JW, et al. ADAM9 expression and regulation in human skin melanoma and melanoma cell lines[J]. Int J Cancer, 2005, 116(6): 853-859.